Biorchestra Shifts Paradigm With Early Diagnosis And Treatment Of Dementia14 January 2020
[BioWatch] [Excellent Bio Venture ①] Biorchestra
Reporter Revision November 28, 2018 15:35
[Photo = Tampo / shutterstock]
The Korea Bio Association held a public investment briefing on 23rd after selecting outstanding companies from the ventures that participated in the Golden Seeds Challenge for the past year. Here are some of the best bio ventures this year.
Dementia is difficult to treat as symptoms of amyloid beta protein accumulation and tau protein hyperphosphorylation progress significantly. Therefore, preemptive response to asymptomatic patients is taking place worldwide.
Indeed, the US Food and Drug Administration (FDA) defined asymptomatic staged dementia as Stage 1 last February, targeting people with pathological symptoms (accumulative accumulations) in the brain even if no behavioral symptoms were present. A guideline for recognizing biomarker-based clinical development is presented.
In response to these trends, Biorchestra has begun early diagnosis of Alzheimer's dementia and development of RNAi-based dementia drugs.
BmD-001, a candidate for gene therapy, is a method of increasing the therapeutic effect by early suppressing the causative agent in patients with asymptomatic dementia. While existing dementia drugs target the already accumulated amyloid beta or tau proteins, bioorchests focus on the proteins responsible for both proteins. It is a concept of inhibiting miRNA regulation before accumulation of two toxic substances.
In other words, it can block both amyloid beta accumulation and tau hyperphosphorylation at the same time, and early treatment can further increase the blocking effect, Bioorchestra said.
“The link between our target protein and amyloid beta and tau is well known in the paper, and we found a miRNA that regulates the target protein with our platform, which is significantly associated with dementia. I confirmed the point. "It is expressed in the brain of animals as well as humans."
Bioorchestra presented three business models with its own miRNA molecule. Development of new dementia drugs that inhibit amyloid and tau through miRNA regulation, early diagnosis of dementia by searching for miRNA molecules, and animal models of dementia administered to animals.
Administration of miRNA modulators to rat models has shown that it effectively blocks tau and amyloid beta toxicants and maintains cognitive abilities. When the drug was administered for 3 months, it was confirmed that the appetite was lowered, and it was confirmed that the fluorescent substance was buried in the cerebrovascular barrier (BBB) to be absorbed in the world's highest yield.
"Our self-developed animal model can cover more phenotypes than the animal or gene TG model injected with the popular amyloid beta," Ryu explained. "Our gene model can cover at least six phenotypes, while gene TG mice cover only four of the nine phenotypes of dementia and two of amyloid beta-injected mice," he said.
The Biorchestra is currently working with the National Primate Center to create the world's first dementia animal model.
Early diagnosis of dementia is more than 90% accurate in a non-invasive way of detecting biomarkers of miRNAs through oral samples such as saliva. The diagnostic kit is undergoing clinical trials with Seoul Daebo Ramae Hospital and will be completed in April next year.
Founded in 2016, Biorchestra currently has 18 employees, including 11 researchers, and recently completed the Series A phase.
Copyrightⓒ 'Honest Knowledge for Health' Comedy.com (http://kormedi.com) / All rights reserved.